Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, made a poster presentation at the 2007 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) in San Diego June 7-11 at the Sheraton San Diego Hotel & Marina. The poster, entitled "Identifying New Immunodominant Myelin Peptides in Relapsing Remitting Multiple Sclerosis Patients" was presented on Sunday, June 10.

The presentation covered laboratory and clinical data from the Company's proprietary T-cell vaccination technology for the treatment of multiple sclerosis. Key highlights of research detailed in the poster presentation include:

-- Data accumulated from over 173 assays (using a T-cell Epitope Analysis Assay (EAA)) have allowed Opexa to identify several myelin protein peptides from myelin basic protein (MBP), myelin proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) as being immunodominant, including some peptides never before reported, and others as being non-reactive,

-- The EAA can be utilized to screen additional or combinations of peptides that have biological significance and;

-- These results have permitted Opexa to optimize the number of myelin peptides across the lengths of MBP, PLP and MOG in the screening assay for Tovaxin(TM) vaccine production to qualify subjects for Opexa's current 150-patient Phase IIb safety and efficacy clinical trial (TERMS).

"These findings mark an important development for Tovaxin, which is a patient-specific autologous T-cell vaccine, because it helps us qualify subjects for our current clinical trial and improves production of the vaccine. The EAA is an important assay for further refinement of the T-cell vaccination technology, which is truly personalized, to make the therapy as efficacious as possible for each patient," said
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... options and research directions , , WASHINGTON, June ... therapeutic option for many patients with interstitial cystitis (IC). IC ... 8 million women and 1.5 million men in the United ... noticed a correlation between allergies and IC. Recently, a urologist ...
... Families of Spinal Muscular Atrophy has just released details ... funded therapeutic pipeline. , , Families of SMA ... Quinazolines to boost gene expression; 2) Tetracyclines at Paratek ... replacement program at California Stem Cell and UCI. ...
Cached Medicine Technology:Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 3
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... 2014 The Beryl Institute announces three ... and four new members of its Patient ... the global community of practice and premier thought leader ... Executive board members are industry leaders who advise on ... insight into market and industry trends. The advisory board ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... HealthDay Reporter , WEDNESDAY, July 30, ... isn,t warranted based on current evidence, a team of ... compete with regular cigarettes might cut tobacco-related deaths and ... on the use and safety of the nicotine-emitting devices. ... a potential for smokers to reduce their health risks ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... company has launched a new online reputation management ... help individuals as well as organizations get rid ... service is the result of extensive research. ReputationChief.Com ... design a service for those who are struggling ...
Breaking Medicine News(10 mins):Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2
... , MONDAY, April 11 (HealthDay News) -- Progressive resistance ... to function better in daily life, researchers say. A ... review of available evidence and concluded that an adult can ... and increase their overall strength by 25 percent to 30 ...
... Ore. An Oregon Health & Science University researcher has ... prevent rejection in organ transplant patients helped treat a rare ... cure and, until now, no known treatment. The clinical ... first randomized, controlled study designed to develop a therapy for ...
... By Steven Reinberg HealthDay Reporter , MONDAY, April ... engines cuts emissions of heart-harmful microscopic particles by 98 percent, ... new study suggests. The very tiny particles found in ... heart disease caused by air pollution, but "if we use ...
... treatment for osteoporosis has often been associated with serious ... Sweden, have now, in mice, found a way of ... that only the skeleton is acted on, current research ... in the respected journal PNAS (Proceedings of the National ...
... A study appearing in the journal Investigational New Drugs ... that two new small molecule inhibitors are showing promise ... common malignant bone tumor, osteosarcoma. These small molecule inhibitors ... spice may serve as a new, non-toxic treatment ...
... Nearly all patients with advanced cancer experience severe pain, and ... regardless of the type or stage of the disease. Pain ... new study, led by Wayne State University,s College of Nursing ... Cancer Institute of the National Institutes of Health, aims to ...
Cached Medicine News:Health News:Progressive Weight Training Can Boost Seniors' Strength 2Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 3Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2Health News:Wayne State leads study to improve management of cancer pain in African Americans 2
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
Medicine Products: